Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MANNKIND CORPMNKD · Entity 4792 | Director | May 20, 2026 | May 23, 2026 |
| ProQR Therapeutics N.V.PRQR · Entity 5946 | Director | March 18, 2026 | March 18, 2026 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MANNKIND CORP
Report date May 20, 2026 · Filed May 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 82,781 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 82,781 · Balance 82,781 F2: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 16,556 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Grant · Acquired 16,556 · Balance 16,556 F2: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F4: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation. |
| Common Stock $0.01 Par ValueSEC Table I · non-derivative | Direct | 36,458 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 36,458 F1: 28,177 shares representing stock options were inadvertently included in Table I holdings on prior filings. |
Filing footnotes · ownership attribution and instrument terms
F1: 28,177 shares representing stock options were inadvertently included in Table I holdings on prior filings.
F2: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F3: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.
F4: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation.
ProQR Therapeutics N.V.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 61,538 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 61,538 |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.89 · Expires 2026-06-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2026-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2027-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.78 · Expires 2028-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.91 · Expires 2029-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2030-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.01 · Expires 2032-02-29 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.41 · Expires 2032-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance Not disclosed F2: 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.98 · Expires 2033-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance Not disclosed F3: 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2034-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance Not disclosed F4: 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2035-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance Not disclosed F5: 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
F2: 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F3: 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F4: 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F5: 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Xilio Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2036-06-10 | Direct | 5,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,000 · Balance 5,000 F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Horizon Therapeutics Public Ltd Co
Report date October 06, 2023 · Filed October 06, 2023
Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 1
1 source rowRow 1 · 2023-10-06 · Disposition to issuer · Disposed 33,156 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2023-10-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-10-06 · Disposition to issuer · Disposed 23,638 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.19 · Expires 2027-08-01 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-10-06 · Disposition to issuer · Disposed 8,150 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.87 · Expires 2028-05-02 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-10-06 · Disposition to issuer · Disposed 32,161 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-07-27 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-10-06 · Disposition to issuer · Disposed 4,016 · Balance 0 F4: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F6: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration. F5: The Ordinary Shares subject to the RSUs vest on July 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
F2: The Option (as defined in footnote 3 to this Form 4) is fully vested.
F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option.
F4: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.
F5: The Ordinary Shares subject to the RSUs vest on July 27, 2024.
F6: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2019 Filed Sep 13, 2019 18:52 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 15,500 | $26.59 | $412,131.05 |
DisclosureSEC source: 0001209191-19-049534 · doc4.xml · nonDerivative · entry 2 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.49 to $26.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 18:52 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 15,500 | $12.19 | $188,945.00 |
DisclosureSEC source: 0001209191-19-049534 · doc4.xml · nonDerivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 17:01 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 8,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044610 · doc4.xml · derivative · entry 3 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,204 Underlying: Ordinary shares · 8,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The shares subject to the restricted stock units vest in three equal annual installments on the anniversary of the grant date (August 2, 2017). F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 17:01 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 3,220 | $24.64 | $79,340.80 |
DisclosureSEC source: 0001209191-19-044610 · doc4.xml · nonDerivative · entry 2 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 19,272 Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 17:01 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 8,203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-044610 · doc4.xml · nonDerivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 22,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:29 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 33,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030394 · doc4.xml · derivative · entry 2 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,557 Underlying: Common Stock · 33,557 shares Expires 2029-05-14 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: Annual Director Award: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:29 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 72,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030394 · doc4.xml · derivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,115 Underlying: Common Stock · 72,115 shares Expires 2029-05-14 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Director Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 03, 2019 Filed May 6, 2019 17:45 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 15,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-027814 · doc4.xml · derivative · entry 4 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 15,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On May 3, 2018, the reporting person was granted 15,320 restricted stock units, vesting in full on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 3, 2018, the reporting person was granted 15,320 restricted stock units, vesting in full on the first anniversary of the grant date. Read SEC document |
| May 03, 2019 Filed May 6, 2019 17:45 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 6,014 | $26.54 | $159,611.56 |
DisclosureSEC source: 0001209191-19-027814 · doc4.xml · nonDerivative · entry 2 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 14,289 Read SEC document |
| May 03, 2019 Filed May 6, 2019 17:45 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 15,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-027814 · doc4.xml · nonDerivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 20,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| May 02, 2019 Filed May 6, 2019 17:45 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 15,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-027814 · doc4.xml · derivative · entry 3 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,390 Underlying: Ordinary shares · 15,390 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| August 02, 2018 Filed Aug 2, 2018 18:49 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 8,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045088 · doc4.xml · derivative · entry 3 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,407 Underlying: Ordinary shares · 8,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The shares subject to the restricted stock units vest in three equal annual installments on the anniversary of the grant date (August 2, 2017). F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| August 02, 2018 Filed Aug 2, 2018 18:49 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 3,220 | $18.18 | $58,539.60 |
DisclosureSEC source: 0001209191-18-045088 · doc4.xml · nonDerivative · entry 2 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 4,983 Read SEC document |
| August 02, 2018 Filed Aug 2, 2018 18:49 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 8,203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-045088 · doc4.xml · nonDerivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 8,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| May 16, 2018 Filed May 22, 2018 20:10 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 65,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-032291 · doc4a.xml · derivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,200 Underlying: Common Stock · 65,200 shares Expires 2028-05-16 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · date: The original Form 4 indicated the wrong transaction date of 5/18/17. The transaction date was 5/16/18. F3 · derivative.exercise_date: Restricted stock unit shall vest immediately, but the shares shall not be delivered until the director leaves the Board. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 15,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028371 · doc4.xml · derivative · entry 2 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,320 Underlying: Ordinary shares · 15,320 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:08 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantStock Option (Right to Buy) · Derivative | 32,161 | $0.00 Strike: $13.87 | $0.00 |
DisclosureSEC source: 0001209191-18-028371 · doc4.xml · derivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,161 Underlying: Ordinary shares · 32,161 shares Expires 2028-05-02 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments from the date of grant. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 18:17 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 24,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047498 · doc4.xml · derivative · entry 2 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,610 Underlying: Ordinary shares · 24,610 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The shares subject to the restricted stock units shall vest in three equal annual installments, beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 18:17 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantStock Option (Right to Buy) · Derivative | 52,232 | $0.00 Strike: $12.19 | $0.00 |
DisclosureSEC source: 0001209191-17-047498 · doc4.xml · derivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,232 Underlying: Ordinary shares · 52,232 shares Expires 2027-08-01 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments from the date of grant. Read SEC document |
| May 18, 2017 Filed May 22, 2017 23:51 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001209191-17-034526 · doc4.xml · derivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-17 F1 · derivative.exercise_date: The option shall vest in 36 equal monthly installments following the date of grant. Read SEC document |
| May 18, 2017 Filed May 18, 2018 14:28 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 65,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031295 · doc4.xml · derivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,200 Underlying: Common Stock · 65,200 shares Expires 2028-05-16 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Restricted stock unit shall vest immediately, but the shares shall not be delivered until the director leaves the Board. Read SEC document |
| May 19, 2016 Filed Feb 1, 2017 14:29 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option · Derivative | 78,400 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001209191-17-006540 · doc5.xml · derivative · entry 4 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,400 Underlying: Common Stock · 78,400 shares Expires 2026-05-19 F4 · derivative.exercise_date: Annual equity award vesting in 36 equal monthly installments commencing one month from date of grant, being fully vested on the third anniversary of grant date. Read SEC document |
| May 19, 2016 Filed Feb 1, 2017 14:29 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006540 · doc5.xml · nonDerivative · entry 3 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,875 F3 · shares: Annual retainer received in equity in lieu of cash. Restricted Stock Units shall vest on the earlier of retirement or removal from board, provided that such retirement or removal occurs more than one year after grant date; death; or five years from grant date. Read SEC document |
| May 19, 2016 Filed Feb 1, 2017 14:29 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006540 · doc5.xml · nonDerivative · entry 2 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,500 F2 · shares: Annual retainer received in equity in lieu of cash. Restricted Stock Units shall vest on the earlier of retirement, removal from board, death or five years from grant date. Read SEC document |
| May 19, 2016 Filed Feb 1, 2017 14:29 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 39,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006540 · doc5.xml · nonDerivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 F1 · shares: Restricted Stock Units with 3-year vesting period; 1/36th vesting every month, being fully vested on the third anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.